التفاصيل البيبلوغرافية
| العنوان: |
A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia |
| المؤلفون: |
Advani, Anjali S.1 advania@ccf.org, Tiu, Ramon1, Saunthararajah, Yogen1, Maciejewski, Jaroslaw1, Copelan, Edward A.1, Sobecks, Ronald1, Sekeres, Mikkael A.1, Bates, Jennifer1, Rush, Mary Lynn1, Tripp, Barbara1, Salvado, August2, Noon, Elysa2, Howard, Matthew3, Jin, Tao4, Hsi, Eric3, Egorin, Merrill J.5, Lim, Kathleen1, Cotta, Claudiu V.3, Price, Courtney1, Kalaycio, Matt1 |
| المصدر: |
Leukemia Research. Dec2010, Vol. 34 Issue 12, p1622-1626. 5p. |
| مصطلحات موضوعية: |
*IMATINIB, *METHANESULFONATES, *CYTARABINE, *CANCER relapse, *ACUTE myeloid leukemia treatment, *GENE expression, *CANCER cell proliferation, *ANTINEOPLASTIC agents, *DRUG efficacy |
| مستخلص: |
Abstract: The c-kit receptor is expressed in 95% of relapsed acute myeloid leukemias (AMLs) and mediates leukemic proliferation. We conducted a Phase 1 study of the c-kit inhibitor, imatinib mesylate (IM), in combination with cytarabine and daunorubicin (7+3) in c-kit+ relapsed AML. IM was dose escalated using a 3 by 3 design. Phosphorylated STAT5 was absent to minimally present in residual blasts on day 14 bone marrows. The maximum tolerated dose of IM was 300mg. The dose-limiting toxicity was Grade 3–4 hepatic toxicity. The CR/CRp rate was 57%. Cytotoxic therapy that includes IM for relapsed AML is well-tolerated and effective. [Copyright &y& Elsevier] |
| قاعدة البيانات: |
Academic Search Index |
